Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.340
+0.130 (5.88%)
At close: Mar 25, 2026, 4:00 PM EDT
2.320
-0.020 (-0.85%)
After-hours: Mar 25, 2026, 4:10 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change
5
Growth
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,411,999
Market Cap
53.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 64 |
| Kezar Life Sciences | 55 |
| Mereo BioPharma Group | 36 |
| Entera Bio | 22 |
| Atossa Therapeutics | 15 |
| Lipocine | 14 |
| OS Therapies | 5 |
ACTU News
- 1 day ago - Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Accesswire
- 16 days ago - Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - GlobeNewsWire
- 4 weeks ago - Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire
- 6 months ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire
- 7 months ago - Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewsWire